ROIV News and Press, Roivant Sciences Ltd. From 01/27/24

2024-01-27 04:45:00 ET Summary Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP Founder Class returned 1.1% for the Fourth Quarter of 2023 and 8.8% for the full year. The fund has returned...

2024-01-25 09:32:10 ET Summary Today, we take a deeper look at Immunovant, Inc., a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for autoimmune diseases. The stock has been on a big run since last summer, as its primary pipeline asset is bein...

2024-01-21 20:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-09 09:00:00 ET Summary Chris DeMuth Jr. discusses his position in uranium and his belief that nuclear energy will play a significant role in the future of energy production. He also updates us on SHF Holdings, a fintech company serving the cannabis industry, and predicts i...

2024-01-07 13:15:25 ET Summary Roivant Sciences operates with an innovative business model through its subsidiaries, specializing in specific therapeutic areas such as immuno-dermatology and autoimmune disorders. Notable achievements include the sale of Telavant to Roche, the succ...

2024-01-04 14:57:58 ET The U.S. presidential hopeful Vivek Ramaswamy sold more than $33M worth of shares of Roivant Sciences ( NASDAQ: ROIV ), the U.K.-based biotech he founded, the Republican candidate disclosed in a regulatory filing on Wednesday. Ramaswamy, who is currently t...

2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...

2024-01-02 10:00:00 ET Summary United Therapeutics Corporation calls itself a "Public Benefit" company. The reality, it is a cynical monopolist about to lose its monopoly. If patent trolling fails, their premium to the entrant could collapse. Disclaimer . ...

2023-12-24 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-21 11:42:39 ET More on Immunovant, Roivant Sciences, etc. 2024 - Liquidia, Burford, And Roivant Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript Immunovant gain...